Compare SLE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | PRLD |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.7M | 260.2M |
| IPO Year | 2019 | 2020 |
| Metric | SLE | PRLD |
|---|---|---|
| Price | $4.49 | $3.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $10.67 | $9.20 |
| AVG Volume (30 Days) | 127.1K | ★ 478.6K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | $2,064,000.00 | ★ $12,140,000.00 |
| Revenue This Year | $18.94 | $258.83 |
| Revenue Next Year | $38.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.41 | 73.43 |
| 52 Week Low | $2.12 | $1.16 |
| 52 Week High | $42.24 | $6.83 |
| Indicator | SLE | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 29.33 |
| Support Level | $4.12 | $2.83 |
| Resistance Level | $4.54 | $3.32 |
| Average True Range (ATR) | 0.38 | 0.24 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 9.01 | 15.29 |
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.